

REFERENCES

1. Author's website: <http://www.ehealthspan.com>
2. **Asvold BO et al. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study.** *Eur J Endocrinol.* 2007 Feb;156(2):181-6.
3. **Razvi S et al. The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a meta-analysis.** *J Clin Endocrinol Metab.* 2008 Aug;93(8):2998-3007
4. **Fernandez-Real JM et al. Thyroid function is intrinsically linked to insulin sensitivity and endothelium-dependent vasodilation in healthy euthyroid subjects.**
J Clin Endocrinol Metab. 2006 Jun 27
5. Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scarlattini M, L'Abbate A, Donato L. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. *Circulation.* 2003;107:708-713.
6. Satar S, Seydaoglu G, Avci A, Sebe A, Karcioğlu O, Topal M. Prognostic value of thyroid hormone levels in acute myocardial infarction: just an epiphenomenon? *Am Heart Hosp J.* 2005;3:227-233.
7. Pavlou HN, Kliridis PA, Panagiotopoulos AA, Goritsas CP, Vassilakos PJ. Euthyroid sick syndrome in acute ischemic syndromes. *Angiology.* 2002;53:699-707.
8. Pingitore A, Galli E, Barison A, Iervasi A, Scarlattini M, Nucci D, L'abbate A, Mariotti R, Iervasi G. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. *J Clin Endocrinol Metab.* 2008;93:1351-1358.
9. Pantos C, Mourouzis I, Cokkinos DV. Rebuilding the post-infarcted myocardium by activating 'physiologic' hypertrophic signaling pathways: the thyroid hormone paradigm. *Heart Fail Rev.* 2008 Sep 5. [Epub ahead of print].
10. **Pantos C et al. Thyroid hormone and "cardiac metamorphosis": potential therapeutic implications.** *Pharmacol Ther.* 2008 May;118(2):277-94.
11. **Danzi S et al. Thyroid hormone treatment to mend a broken heart.** *J Clin Endocrinol Metab.* 2008 Apr;93(4):1172-4
12. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. *Eur Urol.* 2006;50:935-939.
13. Khaw KT, Dowsett M, Folkard E, Bingham S, Wareham N, Luben R, Welch A, Day N. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. *Circulation.* 2007;116:2694-2701.

14. Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. *J Natl Cancer Inst.* 2008;100:170-183.
15. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. *J Urol.* 2005;173:533-536.
16. [Raynaud JP](#) et al. Prostate cancer risk in testosterone-treated men. *J Steroid Biochem Mol Biol.* 2006 Dec;102(1-5):261-6
17. [Khera M](#) et al. The role of testosterone replacement therapy following radical prostatectomy. *Urol Clin North Am.* 2007 Nov;34(4):549-53
18. [Morgentaler A](#), [Schulman C](#). Testosterone and prostate safety. *Front Horm Res.* 2009;37:197-203.
19. [Dobs AS](#), [Morgentaler A](#). Does testosterone therapy increase the risk of prostate cancer? *Endocr Pract.* 2008 Oct;14(7):904-11
20. [Zitzmann M](#). et al. Testosterone and the brain. *Aging Male.* 2006 Dec;9(4):195-9
21. O'Connor DB, Archer J, Hair WM, Wu FC. Exogenous testosterone, aggression, and mood in eugonadal and hypogonadal men. *Physiol Behav.* 2002;75:557-566.
22. Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Jenkins PJ, Mukherjee A, Shalet SM. *Clin Endocrinol (Oxf).* 2006;64:115-121.
23. Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. *Endocr Relat Cancer.* 2006;13:583-592.
24. [No authors listed] Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. *J Clin Endocrinol Metab.* 2001;86:1868-1870.
25. Molitch ME. Diagnosis of GH deficiency in adults--how good do the criteria need to be? *J Clin Endocrinol Metab* 2002 Feb;87(2):473-6
26. Popovic V, Aimaretti G, Casanueva FF, Ghigo E. Hypopituitarism following traumatic brain injury. *Growth Horm IGF Res.* 2005;15:177-184.
27. [Rothman MS](#), The neuroendocrine effects of traumatic brain injury. *J Neuropsychiatry Clin Neurosci.* 2007 Fall;19(4):363-72.
28. Behan LA et al. Neuroendocrine disorders after traumatic brain injury. *J Neurol Neurosurg Psychiatry.* 2008 Jul;79(7):753-9
29. Pettus EH, Wright DW, Stein DG, Hoffman SW. Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. *Brain Res.* 2005;1049:112-119.

30. Djebaili M, Guo Q, Pettus EH, Hoffman SW, Stein DG. The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. *J Neurotrauma*. 2005;22:106-118.
31. Wang JM, Johnston PB, Ball BG, Brinton RD. The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. *J Neurosci*. 2005;25:4706-4718.
32. Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. *Crit Care*. 2008;12:R61.
33. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. *Breast Cancer Res Treat*. 2008;107:103-111.
- 34. Campagnoli C et al. Pregnancy progesterone and progestins in relation to breast cancer risk. Journal of Steroid Biochemistry and Molecular Biology 97 (2005)441-450**
35. Holick MF. High prevalence of vitamin D inadequacy and implications for health. *Mayo Clin Proc*. 2006;81:353-373.
36. Tangpricha V, Pearce EN, Chen TC, Holick MF. Vitamin D insufficiency among free-living healthy young adults. *Am J Med*. 2002;112:659-662.
37. Nesby-O'Dell S, Scanlon KS, Cogswell ME, Gillespie C, Hollis BW, Looker AC, Allen C, Dougherty C, Gunter EW, Bowman BA. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. *Am J Clin Nutr*. 2002;76:187-192.
38. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency [letter]. *Lancet*. 1998;351:805-806.
39. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS. Hypovitaminosis D in medical inpatients. *N Engl J Med*. 1998;338:777-783.
40. Isaia G, Giorgino R, Rini GB, Bevilacqua M, Maugeri D, Adami S. Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. *Osteoporos Int*. 2003;14:577-582.
41. Passeri G, Pini G, Troiano L, Vescovini R, Sansoni P, Passeri M, Guerresi P, Delsignore R, Pedrazzoni M, Franceschi C. Low vitamin D status, high bone turnover, and bone fractures in centenarians. *J Clin Endocrinol Metab*. 2003;88:5109-5115.
42. McKenna MJ. Differences in vitamin D status between countries in young adults and the elderly. *Am J Med*. 1992;93:69-77.

43. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. *Arch Intern Med*. 2008;168:1174-80.
44. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. *JAMA*. 2005;293:2257-2264.
45. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. *Am J Clin Nutr*. 2007;85:1586-1591.
46. Broe KE, Chen TC, Weinberg J, Bischoff-Ferrari HA, Holick MF, Kiel DP. A higher dose of vitamin D reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. *J Am Geriatr Soc*. 2007;55:234-239.
47. Garland CF, Gorham ED, Mohr SB, Grant WB, Garland FC. Breast cancer risk according to serum 25-hydroxyvitamin D: Meta-analysis of dose-response. Presented at: American Association for Cancer Research Annual Meeting; April 12-16, 2008; San Diego, California.
48. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. *JAMA*. 2006;296:2832-2838.
49. Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. *Lancet*. 2001;358:1500-1503.
50. Szeto FL, Sun J, Kong J, Duan Y, Liao A, Madara JL, Li YC. Involvement of the vitamin D receptor in the regulation of NF-kappaB activity in fibroblasts. *J Steroid Biochem Mol Biol*. 2007;103:563-566.
51. Boxer RS, Dauser DA, Walsh SJ, Hager WD, Kenny AM. The association between vitamin D and inflammation with the 6-minute walk and frailty in patients with heart failure. *J Am Geriatr Soc*. 2008;56:454-461.